Unknown

Dataset Information

0

CD8(+) T-cell Immune Evasion Enables Oncolytic Virus Immunotherapy.


ABSTRACT: Although counteracting innate defenses allows oncolytic viruses (OVs) to better replicate and spread within tumors, CD8(+) T-cells restrict their capacity to trigger systemic anti-tumor immune responses. Herpes simplex virus-1 (HSV-1) evades CD8(+) T-cells by producing ICP47, which limits immune recognition of infected cells by inhibiting the transporter associated with antigen processing (TAP). Surprisingly, removing ICP47 was assumed to benefit OV immuno-therapy, but the impact of inhibiting TAP remains unknown because human HSV-1 ICP47 is not effective in rodents. Here, we engineer an HSV-1 OV to produce bovine herpesvirus UL49.5, which unlike ICP47, antagonizes rodent and human TAP. Significantly, UL49.5-expressing OVs showed superior efficacy treating bladder and breast cancer in murine models that was dependent upon CD8(+) T-cells. Besides injected subcutaneous tumors, UL49.5-OV reduced untreated, contralateral tumor size and metastases. These findings establish TAP inhibitor-armed OVs that evade CD8(+) T-cells as an immunotherapy strategy to elicit potent local and systemic anti-tumor responses.

SUBMITTER: Pourchet A 

PROVIDER: S-EPMC4816761 | biostudies-literature | 2016 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

CD8(+) T-cell Immune Evasion Enables Oncolytic Virus Immunotherapy.

Pourchet Aldo A   Fuhrmann Steven R SR   Pilones Karsten A KA   Demaria Sandra S   Frey Alan B AB   Mulvey Matthew M   Mohr Ian I  

EBioMedicine 20160119


Although counteracting innate defenses allows oncolytic viruses (OVs) to better replicate and spread within tumors, CD8(+) T-cells restrict their capacity to trigger systemic anti-tumor immune responses. Herpes simplex virus-1 (HSV-1) evades CD8(+) T-cells by producing ICP47, which limits immune recognition of infected cells by inhibiting the transporter associated with antigen processing (TAP). Surprisingly, removing ICP47 was assumed to benefit OV immuno-therapy, but the impact of inhibiting T  ...[more]

Similar Datasets

| S-EPMC2832755 | biostudies-literature
| S-EPMC7294931 | biostudies-literature
| S-EPMC6264631 | biostudies-literature
| S-EPMC3730318 | biostudies-literature
| S-EPMC7867054 | biostudies-literature
| S-EPMC10811104 | biostudies-literature
| S-EPMC2118677 | biostudies-literature
| S-EPMC7821591 | biostudies-literature
| S-EPMC8864471 | biostudies-literature
| S-EPMC2927075 | biostudies-literature